
Nagla Fawzy Abdel Karim MD
Professor, Internal Medicine, Division of Hematology/Oncology-George Washington University
Join to view full profile
2150 Pennsylvania Ave NWWashington, DC 20037
Phone+1 571-472-1190
Fax+1 571-472-1188
Dr. Abdel Karim is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
Cleveland Clinic Foundation/Fairview HospitalResidency, Internal Medicine, 2003 - 2006
Cairo University School of MedicineClass of 1993
Certifications & Licensure
DC State Medical License 2025 - 2028
VA State Medical License 2022 - 2028
OH State Medical License 2003 - 2027
WV State Medical License 2025 - 2026
GA State Medical License 2018 - 2024
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death ...Steven H Lin, Stephanie L Pugh, Diane Marie Del Valle, Vladimir Roudko, Martin J Edelman
International Journal of Radiation Oncology, Biology, Physics. 2026-09-12 - 14 citationsKRAS mutated NSCLC: past, present, and future directions in a rapidly evolving landscape.Austin Frisch, Eric Martin, So Yeon Kim, Jonathan W Riess, Triparna Sen
The Oncologist. 2025-06-04 - 2 citationsClinical insights: five-year follow-up of KEYNOTE-189 trial outcomes and more.Bobby Se, Athar Eysa, Nagla Karim
Translational Lung Cancer Research. 2024-08-31
Lectures
- Phase I trial of chloroquine (CQ)/hydroxychloroquine (HCQ) in combination with carboplatin-gemcitabine (CG) in patients with advanced solid tumors.2019 ASCO Annual Meeting - 6/1/2019
- Correlation between K-RAS mutant subsets, TP53 mutation, and PD-L1 status in non-small cell lung cancer (NSCLC).2019 ASCO Annual Meeting - 6/1/2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: